Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Net Cash Flow (2023 - 2025)

NewAmsterdam Pharma's Net Cash Flow history spans 3 years, with the latest figure at -$48.3 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 113.54% year-over-year to -$48.3 million; the TTM value through Dec 2025 reached -$293.2 million, down 166.92%, while the annual FY2025 figure was -$293.2 million, 166.92% down from the prior year.
  • Net Cash Flow for Q4 2025 was -$48.3 million at NewAmsterdam Pharma, down from -$24.4 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $357.0 million in Q4 2024 and bottomed at -$193.4 million in Q2 2025.
  • The 3-year median for Net Cash Flow is -$28.3 million (2023), against an average of $1.0 million.
  • The largest annual shift saw Net Cash Flow surged 1179.15% in 2024 before it crashed 290.43% in 2025.
  • A 3-year view of Net Cash Flow shows it stood at -$33.1 million in 2023, then soared by 1179.15% to $357.0 million in 2024, then crashed by 113.54% to -$48.3 million in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Net Cash Flow are -$48.3 million (Q4 2025), -$24.4 million (Q3 2025), and -$193.4 million (Q2 2025).